Hemoptysis News and Research

RSS
First-ever successful use of modified double-decker technique for scimitar syndrome in a child

First-ever successful use of modified double-decker technique for scimitar syndrome in a child

Drug combination can prolong survival and improve quality of life in patients with advanced lung cancer

Drug combination can prolong survival and improve quality of life in patients with advanced lung cancer

Italian study finds SARS-CoV-2 in clinical samples collected before December 2019

Italian study finds SARS-CoV-2 in clinical samples collected before December 2019

Accurate detection of D-dimer for pulmonary embolism among ER patients with suspected COVID-19

Accurate detection of D-dimer for pulmonary embolism among ER patients with suspected COVID-19

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

Insmed reports top-line data from Phase 3 study of new treatment in patients with NTM lung disease

Insmed reports top-line data from Phase 3 study of new treatment in patients with NTM lung disease

Simple diagnostic algorithm to assess pulmonary embolism risk can help reduce rate of CTPA imaging

Simple diagnostic algorithm to assess pulmonary embolism risk can help reduce rate of CTPA imaging

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare receives FDA approval for Adempas tablets

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta announces results from ganetespib Phase 2b trial on NSCLC

LVRC safe and effective choice for patients with severe heterogeneous emphysema

LVRC safe and effective choice for patients with severe heterogeneous emphysema

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.